China SXT Pharmaceuticals, Inc

(NASDAQ:SXTC)

Latest On China SXT Pharmaceuticals, Inc (SXTC):

Date/Time Type Description Signal Details
2023-05-10 20:55 ESTNewsChina SXT Pharmaceuticals receives 180-day extension to regain Nasdaq minimum bid price complianceN/A
2022-05-18 14:05 ESTNewsChina SXT Pharmaceuticals announces 1-for-20 reverse stock splitN/A
2022-03-29 12:04 ESTNewsChina SXT Pharmaceuticals climbs on heavy volumeN/A
2022-03-15 09:55 ESTNewsChina SXT Pharmaceuticals to raise $2.8M in convertible promissory note offeringN/A
2022-01-18 11:17 ESTNewsChina SXT Pharmaceuticals slumps on pricing $3.5M stock, pre-funded warrants offeringN/A
2021-12-16 14:24 ESTNewsChina SXT Pharmaceuticals receives Nasdaq notification for minimum bid price requirementN/A
2021-02-23 00:49 ESTStock SplitA stock split has occured on Feb 22, 2021 with a split factor of 1:4.Neutral
2021-02-19 16:46 ESTNewsChina SXT Pharmaceuticals announces 1:4 reverse share splitN/A
2021-01-31 18:10 ESTFinancialsCompany financials have been released.Neutral
2020-11-26 21:42 ESTFinancialsCompany financials have been released.Neutral
2020-11-08 01:01 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 17:15 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 14:09 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 06:22 ESTFinancialsCompany financials have been released.Neutral
2020-09-10 06:18 ESTNewsChina SXT Pharmaceuticals granted 180-day extension to regain compliance with NasdaqN/A
2020-08-14 10:15 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 09:38 ESTFinancialsCompany financials have been released.Neutral
2020-08-02 13:39 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 17:59 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 05:57 ESTFinancialsCompany financials have been released.Neutral
2020-07-29 22:04 ESTFinancialsCompany financials have been released.Neutral
2020-07-27 13:53 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 18:35 ESTFinancialsCompany financials have been released.Neutral
2020-07-09 10:06 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 17:53 ESTFinancialsCompany financials have been released.Neutral
2020-06-19 13:46 ESTFinancialsCompany financials have been released.Neutral
2020-06-14 05:49 ESTFinancialsCompany financials have been released.Neutral
2020-06-12 06:16 ESTFinancialsCompany financials have been released.Neutral
2020-05-27 06:23 ESTFinancialsCompany financials have been released.Neutral
2020-05-21 01:57 ESTFinancialsCompany financials have been released.Neutral
2020-05-06 06:31 ESTFinancialsCompany financials have been released.Neutral
2020-05-01 05:54 ESTFinancialsCompany financials have been released.Neutral
2020-04-26 05:36 ESTFinancialsCompany financials have been released.Neutral
2020-04-03 21:57 ESTFinancialsCompany financials have been released.Neutral
2020-03-25 21:34 ESTFinancialsCompany financials have been released.Neutral
2020-02-28 05:07 ESTFinancialsCompany financials have been released.Neutral
2020-02-27 22:52 ESTFinancialsCompany financials have been released.Neutral
2020-02-22 00:49 ESTFinancialsCompany financials have been released.Neutral
2020-02-18 00:34 ESTFinancialsCompany financials have been released.Neutral
2020-02-13 00:49 ESTFinancialsCompany financials have been released.Neutral
2020-02-07 00:55 ESTFinancialsCompany financials have been released.Neutral
2020-02-01 00:51 ESTFinancialsCompany financials have been released.Neutral
2020-01-29 00:48 ESTFinancialsCompany financials have been released.Neutral
2020-01-28 00:53 ESTFinancialsCompany financials have been released.Neutral
2020-01-25 00:39 ESTFinancialsCompany financials have been released.Neutral
2020-01-16 00:54 ESTFinancialsCompany financials have been released.Neutral
2019-12-22 00:23 ESTFinancialsCompany financials have been released.Neutral
2019-12-17 00:40 ESTFinancialsCompany financials have been released.Neutral
2019-11-29 00:26 ESTFinancialsCompany financials have been released.Neutral
2019-11-28 00:37 ESTFinancialsCompany financials have been released.Neutral

About China SXT Pharmaceuticals, Inc (SXTC):

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. It offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. The company provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of May 2, 2020, it served 116 pharmaceutical companies, 56 pharmacies, and 76 hospitals. The company was founded in 2005 and is based in Taizhou, China.

SXTC Quotes by TradingView

See Advanced Chart

General

  • Name China SXT Pharmaceuticals, Inc
  • Symbol SXTC
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDrug Manufacturers-Specialty & Generic
  • Full Time Employees 97
  • Last Split Factor1:4
  • Last Split Date2021-02-22
  • Fiscal Year EndMarch
  • IPO Date2019-01-04
  • Gic SectorConsumer Staples
  • Gic GroupHousehold & Personal Products
  • Gic IndustryPersonal Products
  • Gic SubIndustryPersonal Products
  • Web URLhttp://www.sxtchina.com
View More

Valuation

  • Trailing PE 12.51
  • Price/Sales (Trailing 12 Mt.) 3.06
  • Price/Book (Most Recent Quarter) 1.49
  • Enterprise Value Revenue 2.98
  • Enterprise Value EBITDA 40.79
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Profit Margin -113%
  • Operating Margin 1%
  • Return on Equity -44%
  • Revenue 5.81 million
  • Earnings Per Share $0.08
  • Revenue Per Share $0.58
  • Gross Profit 2.7 million
  • Quarterly Earnings Growth 20.1%
View More

Highlights

  • Market Capitalization 35.22 million
  • EBITDA 424668
  • Book Value Per Share $1.19
View More

Share Statistics

  • Shares Outstanding 15.51 million
  • Shares Float 11.96 million
  • % Held by Insiders 1370%
  • % Held by Institutions 8.29%
  • Shares Short 327342
  • Shares Short Prior Month 360558
  • Short Ratio 0.12
  • Short % of Float 2%
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta -0.23
  • 52 Week High $5.12
  • 52 Week Low $0.89
  • 50 Day Moving Average 2.75
  • 200 Day Moving Average 1.69
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

China SXT Pharmaceuticals, Inc (SXTC) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

China SXT Pharmaceuticals, Inc (SXTC) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-06-302020-09-30$N/A$0.05$0.00
2020-03-312020-06-30$N/A$0.05$0.00
2019-12-312020-03-31$N/A-$0.60$0.00
2019-09-302019-12-31$N/A-$0.60$0.00
2019-06-302019-09-30$N/A-$0.21$0.00
2019-03-312019-06-30$1.55 million-$0.21$0.00
2018-12-312019-03-31$1.55 million$0.05$0.00
2018-09-302018-12-31$1.96 million$0.05$0.00
2018-06-302018-09-30$1.96 million$0.10$0.00
2018-03-312018-06-30$1.43 million$0.10$0.00
2017-12-312018-03-31$N/A$0.04$0.00
2017-06-302017-09-30$N/A$0.08$0.00
2017-03-312017-06-30$4.88 million$0.08$0.00
2016-12-312017-03-31$N/A$0.08$0.00

China SXT Pharmaceuticals, Inc (SXTC) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

China SXT Pharmaceuticals, Inc (SXTC) Chart:

China SXT Pharmaceuticals, Inc (SXTC) News:

Below you will find a list of latest news for China SXT Pharmaceuticals, Inc (SXTC) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

China SXT Pharmaceuticals, Inc (SXTC) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest SXTC Trades:

Date Shares Price
Jun 13, 2022 5:29 PM EST100$1.72
Jun 13, 2022 5:30 PM EST100$1.715
Jun 13, 2022 5:30 PM EST100$1.715
Jun 13, 2022 7:53 PM EST200$1.715
Jun 13, 2022 7:53 PM EST400$1.715

China SXT Pharmaceuticals, Inc (SXTC) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-05-226-K/AReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1723980/000121390020013317/0001213900-20-013317-index.htm
2018-01-03UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1723980/000000000018000182/0000000000-18-000182-index.htm
2018-02-05UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1723980/000000000018003936/0000000000-18-003936-index.htm
2018-03-16UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1723980/000000000018008179/0000000000-18-008179-index.htm
2018-04-10UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1723980/000000000018010736/0000000000-18-010736-index.htm
2018-05-01UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1723980/000000000018013382/0000000000-18-013382-index.htm
2018-09-13UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1723980/000000000018028528/0000000000-18-028528-index.htm
2019-06-13UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1723980/000000000019009829/0000000000-19-009829-index.htm
2017-12-04F-1Registration statement for certain foreign private issuershttps://www.sec.gov/Archives/edgar/data/1723980/000114420417062247/0001144204-17-062247-index.htm
2018-01-19F-1/ARegistration statement for certain foreign private issuershttps://www.sec.gov/Archives/edgar/data/1723980/000114420418002891/0001144204-18-002891-index.htm
2018-01-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1723980/000114420418002894/0001144204-18-002894-index.htm
2018-03-06F-1/ARegistration statement for certain foreign private issuershttps://www.sec.gov/Archives/edgar/data/1723980/000114420418013133/0001144204-18-013133-index.htm
2018-03-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1723980/000114420418013137/0001144204-18-013137-index.htm
2018-03-28F-1/ARegistration statement for certain foreign private issuershttps://www.sec.gov/Archives/edgar/data/1723980/000114420418017559/0001144204-18-017559-index.htm
2018-03-28CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1723980/000114420418017566/0001144204-18-017566-index.htm
2018-04-20F-1/ARegistration statement for certain foreign private issuershttps://www.sec.gov/Archives/edgar/data/1723980/000114420418021554/0001144204-18-021554-index.htm
2018-04-20CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1723980/000114420418021581/0001144204-18-021581-index.htm
2018-05-07F-1/ARegistration statement for certain foreign private issuershttps://www.sec.gov/Archives/edgar/data/1723980/000114420418025692/0001144204-18-025692-index.htm
2018-05-07CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1723980/000114420418025698/0001144204-18-025698-index.htm
2018-06-07FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1723980/000114420418033276/0001144204-18-033276-index.htm
2018-08-17F-1/ARegistration statement for certain foreign private issuershttps://www.sec.gov/Archives/edgar/data/1723980/000114420418045380/0001144204-18-045380-index.htm
2018-09-17F-1/ARegistration statement for certain foreign private issuershttps://www.sec.gov/Archives/edgar/data/1723980/000114420418049635/0001144204-18-049635-index.htm
2018-09-17CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1723980/000114420418049638/0001144204-18-049638-index.htm
2018-09-26CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1723980/000114420418050940/0001144204-18-050940-index.htm
2018-09-26CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1723980/000114420418050942/0001144204-18-050942-index.htm
2018-09-27FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1723980/000114420418051157/0001144204-18-051157-index.htm
2018-10-03424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1723980/000114420418052197/0001144204-18-052197-index.htm
2018-11-14424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1723980/000114420418060000/0001144204-18-060000-index.htm
2018-12-268-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1723980/000114420418066196/0001144204-18-066196-index.htm
2019-02-15SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1723980/000114420419008588/0001144204-19-008588-index.htm
2019-05-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1723980/000114420419024432/0001144204-19-024432-index.htm
2019-03-05424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1723980/000121390019003591/0001213900-19-003591-index.htm
2019-03-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1723980/000121390019005023/0001213900-19-005023-index.htm
2019-04-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1723980/000121390019006552/0001213900-19-006552-index.htm
2019-05-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1723980/000121390019007812/0001213900-19-007812-index.htm
2019-05-30F-1Registration statement for certain foreign private issuershttps://www.sec.gov/Archives/edgar/data/1723980/000121390019009831/0001213900-19-009831-index.htm
2019-06-21F-1/ARegistration statement for certain foreign private issuershttps://www.sec.gov/Archives/edgar/data/1723980/000121390019011250/0001213900-19-011250-index.htm
2019-06-21CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1723980/000121390019011256/0001213900-19-011256-index.htm
2019-06-25CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1723980/000121390019011435/0001213900-19-011435-index.htm
2019-07-31NT 20-FNotification of inability to timely file Form 20-Fhttps://www.sec.gov/Archives/edgar/data/1723980/000121390019014119/0001213900-19-014119-index.htm
2019-07-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1723980/000121390019014165/0001213900-19-014165-index.htm
2019-08-1520-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1723980/000121390019016026/0001213900-19-016026-index.htm
2019-08-1920-F/AAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1723980/000121390019016250/0001213900-19-016250-index.htm
2019-11-05424B8Prospectus filed pursuant to Rule 424(b)(8)https://www.sec.gov/Archives/edgar/data/1723980/000121390019022024/0001213900-19-022024-index.htm
2019-12-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1723980/000121390019026190/0001213900-19-026190-index.htm
2020-01-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1723980/000121390020002223/0001213900-20-002223-index.htm
2020-03-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1723980/000121390020005362/0001213900-20-005362-index.htm
2020-03-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1723980/000121390020005884/0001213900-20-005884-index.htm
2020-03-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1723980/000121390020008197/0001213900-20-008197-index.htm
2020-04-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1723980/000121390020009835/0001213900-20-009835-index.htm
2020-05-226-K/AReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1723980/000121390020013317/0001213900-20-013317-index.htm
2020-07-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1723980/000121390020017121/0001213900-20-017121-index.htm
2020-07-3120-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1723980/000121390020019503/0001213900-20-019503-index.htm
2019-01-02CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1723980/000135445719000002/0001354457-19-000002-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1723980/000139382520000087/0001393825-20-000087-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1723980/000149315220002422/0001493152-20-002422-index.htm
2018-09-28EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1723980/999999999518002492/9999999995-18-002492-index.htm
2019-06-27EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1723980/999999999519001461/9999999995-19-001461-index.htm